(VIANEWS) – Extra Space Storage (EXR), Badger Meter (BMI), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Extra Space Storage (EXR)
29.3% sales growth and 22.19% return on equity
Extra Space Storage Inc., headquartered in Salt Lake City, Utah, is a self-administered and self-managed REIT and a member of the S&P 500. As of June 30, 2023, the Company owned and/or operated 2,438 self-storage stores in 41 states and Washington, D.C. The Company's stores comprise approximately 1.7 million units and approximately 184.0 million square feet of rentable space. With the completed Life Storage Merger on July 20, 2023, Extra Space currently has over 3,500 locations under the Extra Space, Life Storage and Storage Express brands, and it is the largest operator of self-storage properties in the United States. The Company offers customers a wide selection of conveniently located and secure storage units across the country, including boat storage, RV storage and business storage.
Earnings Per Share
As for profitability, Extra Space Storage has a trailing twelve months EPS of $6.12.
PE Ratio
Extra Space Storage has a trailing twelve months price to earnings ratio of 17.12. Meaning, the purchaser of the share is investing $17.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.19%.
Sales Growth
Extra Space Storage’s sales growth is 42.9% for the present quarter and 29.3% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 41.2% and a negative 11.2%, respectively.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 13, 2023, the estimated forward annual dividend rate is 2.44 and the estimated forward annual dividend yield is 2.34%.
2. Badger Meter (BMI)
13.7% sales growth and 18.66% return on equity
Badger Meter, Inc. manufactures and markets flow measurement, quality, control, and communication solutions in the United States, Asia, Canada, Europe, Mexico, the Middle East, and internationally. It offers mechanical or static water meters, and related radio and software technologies and services to municipal water utilities. The company also provides flow instrumentation products, including meters, valves, and other sensing instruments to measure and control fluids going through a pipe or pipeline, including water, air, steam, oil, and other liquids and gases to original equipment manufacturers as the primary flow measurement device within a product or system, as well as through manufacturers' representatives. Its flow instrumentation products are used in water/wastewater, heating, ventilating and air conditioning, and corporate sustainability markets. In addition, the company offers ORION Migratable for automatic meter reading; ORION (SE) for traditional fixed network applications; and ORION Cellular for infrastructure-free fixed network meter reading solution, as well as BEACON advanced metering analytics, a secure cloud-hosted software suite that establishes alerts for specific conditions and allows consumer engagement tools that permit end water customers to view and manage their water usage activity. It also serves water utilities, industrial, and other industries. The company sells its products directly, as well as through resellers and representatives. Badger Meter, Inc. was founded in 1905 and is headquartered in Milwaukee, Wisconsin.
Earnings Per Share
As for profitability, Badger Meter has a trailing twelve months EPS of $2.89.
PE Ratio
Badger Meter has a trailing twelve months price to earnings ratio of 47.62. Meaning, the purchaser of the share is investing $47.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Badger Meter’s EBITDA is 5.78.
Moving Average
Badger Meter’s value is below its 50-day moving average of $152.45 and under its 200-day moving average of $138.55.
3. Vertex Pharmaceuticals (VRTX)
9.1% sales growth and 24.56% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.93.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 27.55. Meaning, the purchaser of the share is investing $27.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.56%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 0.7% and positive 1.9% for the next.
Previous days news about Vertex Pharmaceuticals(VRTX)
- Vertex pharmaceuticals (vrtx) declines more than market: some information for investors. According to Zacks on Friday, 27 October, "Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. ", "Looking at its valuation, Vertex Pharmaceuticals is holding a Forward P/E ratio of 24.81. "
4. DXP Enterprises (DXPE)
5.1% sales growth and 15.49% return on equity
DXP Enterprises, Inc., together with its subsidiaries, engages in distributing maintenance, repair, and operating (MRO) products, equipment, and services to the energy and industrial customers primarily in the United States and Canada. It operates through three segments: Service Centers (SC), Supply Chain Services (SCS), and Innovative Pumping Solutions (IPS). The SC segment offers MRO products, equipment, and integrated services, including technical expertise and logistics services. It offers a range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products, and safety services categories. This segment serves customers in the oil and gas, food and beverage, petrochemical, transportation, other general industrial, mining, construction, chemical, municipal, agriculture, and pulp and paper industries. The SCS segment manages procurement and inventory management solutions; and offers outsourced MRO solutions for sourcing MRO products, including inventory optimization and management, store room management, transaction consolidation and control, vendor oversight and procurement cost optimization, productivity improvement, and customized reporting services. Its programs include SmartAgreement, a procurement solution for various MRO categories; SmartBuy, an on-site or centralized MRO procurement solution; SmartSource, an on-site procurement and storeroom management solution; SmartStore, an e-Catalog solution; SmartVend, an industrial dispensing solution; and SmartServ, an integrated service pump solution. The IPS segment fabricates and assembles custom-made pump packages, remanufactures pumps, and manufactures branded private label pumps. The company was founded in 1908 and is based in Houston, Texas.
Earnings Per Share
As for profitability, DXP Enterprises has a trailing twelve months EPS of $3.
PE Ratio
DXP Enterprises has a trailing twelve months price to earnings ratio of 10.9. Meaning, the purchaser of the share is investing $10.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.49%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.4%, now sitting on 1.65B for the twelve trailing months.
